查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424050

皮下免疫球蛋白市场、份额、规模、趋势、产业分析报告：按最终用途、地区和细分市场预测，2024-2032年

Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Application (Primary Immunodeficiency Disease, Secondary Immunodeficiency Disease); By End Use; By Region; Segment Forecast, 2024- 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，到2032年，全球皮下免疫球蛋白市场规模预计将达到330.2亿美元。 该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

由于适应症的扩大和治疗用途的扩大，皮下免疫球蛋白市场正在创造利润丰厚的机会。 皮下注射免疫球蛋白製剂不仅限于其在免疫缺陷疾病中的传统用途，而且还被用于自体免疫疾病、神经病学和皮肤病学等领域。 研究显示免疫球蛋白在慢性发炎性脱髓鞘性多发性神经病变 (CIDP)、重症肌无力和多灶性运动神经病变等疾病中的潜在用途正在推动其应用的增加。 皮下免疫球蛋白製剂的多功能性和患者友好的给药方法使其成为各种医疗领域有前途的治疗选择，使市场多样化并扩大适应症和治疗领域，以满足不断变化的医疗保健环境。

儿科应用对于推动皮下免疫球蛋白市场机会至关重要。 皮下注射免疫球蛋白作为治疗儿童免疫缺陷疾病的一种有前途的治疗方法正在获得认可，提供了一种侵入性较小且方便的选择。 皮下注射可提高治疗依从性，并满足对儿科友善医疗保健解决方案不断增长的需求。 它着重于儿科族群的有效性和安全性，并解决儿童免疫缺陷疾病日益流行的问题。

以患者为中心的医疗趋势，尤其是针对免疫缺陷病等慢性疾病的趋势，正在推动对家庭治疗的需求。 这种方法提高了患者的舒适度和便利性，并减轻了医疗机构的负担。 为患者和照护者提供易于使用的输液设备和教育资源进一步支持家庭管理。 随着医疗保健向分散模式发展，并且患者希望对自己的护理有更多的控制权，皮下免疫球蛋白市场反映了医疗保健服务不断变化的格局，并致力于提供易于使用且有效的家庭解决方案，正在不断成长。

製药公司越来越多地瞄准发展中地区，在这些地区，皮下免疫球蛋白的便利性和可及性使其成为一种流行的治疗方法。 这些新兴市场不断扩大的医疗基础设施和对先进治疗的认识不断提高，为皮下免疫球蛋白的广泛使用创造了有利的环境。 透过涵盖服务不足的人群，该市场与提供有效的免疫缺陷治疗的全球目标保持一致。 随着这些地区医疗保健系统的进步，皮下免疫球蛋白市场处于有利位置，可以挖掘未开发的潜力，提供创新的解决方案，并推动这些充满活力和不断扩大的市场的成长。我就是。

皮下免疫球蛋白市场报告亮点

2023年，原发性免疫缺陷类别由于家庭给药、全身副作用减少和患者满意度提高而占据了很大的市场份额。

2023年，医院领域因其在免疫缺陷疾病、神经系统疾病和自体免疫疾病方面的应用而占据了很大的销售份额。

2023 年，由于患者意识的提高、医疗保健支出的增加以及以患者为中心的医疗，北美地区主导了全球市场。

由于生物产品实验室、Biotest AG、CSL Behring、Grifols、Laboratoire francais du Fractionnement et des Biotechnologies、Octapharma 和 Takeda Pharmaceutical Company 等具有全球影响力的市场参与者的存在，市场竞争非常激烈。

目录

第 1 章简介

第 2 章执行摘要

第 3 章研究方法

第 4 章全球皮下免疫球蛋白市场洞察

  • 皮下免疫球蛋白市场 - 产业概况
  • 皮下免疫球蛋白市场动态
    • 促进因素和机会
      • 免疫缺陷疾病发生率的增加预计将刺激对该产品的需求
      • 以患者为中心的方法预计将推动市场成长
    • 抑制因素和挑战
      • 高昂的处理成本可能会阻碍市场成长
  • PESTLE分析
  • 皮下免疫球蛋白产业的趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第 5 章全球皮下免疫球蛋白市场（依应用）

  • 主要发现
  • 简介
  • 原发性免疫缺陷
  • 继发性免疫缺陷

第 6 章全球皮下免疫球蛋白市场（依最终用途）

  • 主要发现
  • 简介
  • 诊所
  • 医院
  • 居家护理
  • 其他

第 7 章按地区划分的全球皮下免疫球蛋白市场

  • 主要发现
  • 简介
    • 2019-2032 年皮下免疫球蛋白市场评估（按地区）
  • 皮下免疫球蛋白市场 - 北美
    • 北美：皮下免疫球蛋白市场，依最终用途，2019-2032 年
    • 北美：皮下免疫球蛋白市场，按应用划分，2019-2032 年
    • 皮下免疫球蛋白市场－美国
    • 皮下免疫球蛋白市场 - 加拿大
  • 皮下免疫球蛋白市场 - 欧洲
    • 欧洲：皮下免疫球蛋白市场，依最终用途，2019-2032 年
    • 欧洲：皮下免疫球蛋白市场，依应用划分，2019-2032 年
    • 皮下免疫球蛋白市场 - 英国
    • 皮下免疫球蛋白市场 - 法国
    • 皮下免疫球蛋白市场 - 德国
    • 皮下免疫球蛋白市场 - 义大利
    • 皮下免疫球蛋白市场 - 西班牙
    • 皮下免疫球蛋白市场 - 荷兰
    • 皮下免疫球蛋白市场 - 俄罗斯
  • 皮下免疫球蛋白市场 - 亚太地区
    • 亚太地区：皮下免疫球蛋白市场，依最终用途，2019-2032 年
    • 亚太地区：皮下免疫球蛋白市场，依应用划分，2019-2032 年
    • 皮下免疫球蛋白市场 - 中国
    • 皮下免疫球蛋白市场 - 印度
    • 皮下免疫球蛋白市场 - 马来西亚
    • 皮下免疫球蛋白市场 - 日本
    • 皮下免疫球蛋白市场 - 印尼
    • 皮下免疫球蛋白市场 - 韩国
  • 皮下免疫球蛋白市场 - 中东和非洲
    • 中东和非洲：皮下免疫球蛋白市场，以最终用途，2019-2032 年
    • 中东和非洲：皮下免疫球蛋白市场，按应用划分，2019-2032 年
    • 皮下免疫球蛋白市场 - 沙乌地阿拉伯
    • 皮下免疫球蛋白市场 - 阿拉伯联合大公国
    • 皮下免疫球蛋白市场 - 以色列
    • 皮下免疫球蛋白市场 - 南非
  • 皮下免疫球蛋白市场 - 拉丁美洲
    • 拉丁美洲：皮下免疫球蛋白市场，依最终用途，2019-2032 年
    • 拉丁美洲：皮下免疫球蛋白市场，按应用划分，2019-2032 年
    • 皮下免疫球蛋白市场 - 墨西哥
    • 皮下免疫球蛋白市场 - 巴西
    • 皮下免疫球蛋白市场 - 阿根廷

第 8 章竞争态势

  • 扩张与收购分析
    • 扩大
    • 收购
  • 伙伴关係/协作/协议/揭露

第 9 章公司简介

  • ADMA Biologics
  • Bio Product Laboratory
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring
  • Emergent BioSolutions
  • Grifols
  • Hansa Biopharma
  • InVivo Biotech Services
  • Kedrion Biopharma
  • Kamada Ltd.
  • Laboratoire francais du Fractionnement et des Biotechnologies
  • Octapharma
  • Shenzhen Weiguang Biological Products Co., Ltd.
  • Takeda Pharmaceutical Company
Product Code: PM4416

The global Subcutaneous Immunoglobulin market size is expected to reach USD 33.02 billion by 2032, according to a new study by Polaris Market Research. The report "Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Application (Primary Immunodeficiency Disease, Secondary Immunodeficiency Disease); By End Use; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Expanded indications and therapeutic applications are creating lucrative opportunities in the subcutaneous immunoglobulin market. Beyond its traditional use in immunodeficiency disorders, it is gaining traction in autoimmune diseases, neurology, and dermatology. Research showcasing its potential benefits in conditions like chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, and multifocal motor neuropathy is driving increased adoption. The versatility and patient-friendly administration of subcutaneous immunoglobulin position it as a promising therapeutic option across diverse medical domains, diversifying the market and responding to the evolving healthcare landscape with expanded indications and therapeutic areas.

Pediatric applications are crucial in driving opportunities within the subcutaneous immunoglobulin market. Subcutaneous immunoglobulin is gaining traction as a promising treatment for immunodeficiency disorders in children, offering a less invasive and more convenient alternative. The subcutaneous administration method enhances treatment adherence, meeting the growing demand for child-friendly healthcare solutions. With a focus on efficacy and safety for the pediatric population, it addresses the rising prevalence of immunodeficiency disorders in children.

The trend towards patient-centric care, particularly for chronic conditions like immunodeficiency disorders, has intensified the demand for home-based administration. This approach enhances patient comfort and convenience and reduces the strain on healthcare facilities. The availability of user-friendly infusion devices and educational resources for patients and caregivers further supports home-based administration. As healthcare evolves towards decentralized models and patients desire more control over their treatment, the subcutaneous immunoglobulin market is growing by offering accessible and effective home-based solutions, reflecting the shifting landscape of healthcare delivery.

Pharmaceutical companies are increasingly targeting developing regions, where subcutaneous immunoglobulin's convenience and accessibility make it a sought-after treatment. Expanding healthcare infrastructure and growing awareness of advanced therapies in these emerging markets create a conducive environment for subcutaneous immunoglobulin adoption. By reaching underserved populations, the market aligns with the global goal of providing effective immunodeficiency disorder therapies. As healthcare systems in these regions advance, the subcutaneous immunoglobulin market is well-positioned to capitalize on the untapped potential, offering innovative solutions and fostering growth in these dynamic and expanding markets.

Subcutaneous Immunoglobulin Market Report Highlights

In 2023, the primary immunodeficiency disease segment accounted for significant market share owing to home-based administration, reduced systemic side effects, and improved patient satisfaction.

In 2023, the hospital segment held significant revenue share owing to application in immunodeficiency disorders, neurological conditions, and autoimmune disorders.

In 2023, North America region dominated the global market due to increasing patient awareness, rising healthcare expenditure, and patient-centric care.

The market is highly competitive owing to the existence of market players with a global presence, including Bio Product Laboratory, Biotest AG, CSL Behring, Grifols, Laboratoire francais du Fractionnement et des Biotechnologies, Octapharma, and Takeda Pharmaceutical Company among others.

Polaris Market Research has segmented the Subcutaneous Immunoglobulin market report based on application, end use, and region:

Subcutaneous Immunoglobulin, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Primary Immunodeficiency Disease
  • Secondary Immunodeficiency Disease

Subcutaneous Immunoglobulin, End Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Clinics
  • Hospitals
  • Homecare
  • Others

Subcutaneous Immunoglobulin, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Netherlands
  • Spain
  • Russia
  • Asia Pacific
  • Japan
  • China
  • India
  • Malaysia
  • Indonesia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Subcutaneous Immunoglobulin Market Insights

  • 4.1. Subcutaneous Immunoglobulin Market - Industry Snapshot
  • 4.2. Subcutaneous Immunoglobulin Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing incidence of immunodeficiency disorders is projected to spur the product demand
      • 4.2.1.2. Patient-centric approach is expected to drive market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment is likely to impede the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Subcutaneous Immunoglobulin Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Subcutaneous Immunoglobulin Market, by Application

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Subcutaneous Immunoglobulin, by Application, 2019-2032 (USD Billion)
  • 5.3. Primary Immunodeficiency Disease
    • 5.3.1. Global Subcutaneous Immunoglobulin Market, by Primary Immunodeficiency Disease, by Region, 2019-2032 (USD Billion)
  • 5.4. Secondary Immunodeficiency Disease
    • 5.4.1. Global Subcutaneous Immunoglobulin Market, by Secondary Immunodeficiency Disease, by Region, 2019-2032 (USD Billion)

6. Global Subcutaneous Immunoglobulin Market, by End Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • 6.3. Clinics
    • 6.3.1. Global Subcutaneous Immunoglobulin Market, by Clinics, by Region, 2019-2032 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Global Subcutaneous Immunoglobulin Market, by Hospitals, by Region, 2019-2032 (USD Billion)
  • 6.5. Homecare
    • 6.5.1. Global Subcutaneous Immunoglobulin Market, by Homecare, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Subcutaneous Immunoglobulin Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Subcutaneous Immunoglobulin Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Subcutaneous Immunoglobulin Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Subcutaneous Immunoglobulin Market - North America
    • 7.3.1. North America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.3.2. North America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.3.3. Subcutaneous Immunoglobulin Market - U.S.
      • 7.3.3.1. U.S.: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.3.4. Subcutaneous Immunoglobulin Market - Canada
      • 7.3.4.1. Canada: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.4. Subcutaneous Immunoglobulin Market - Europe
    • 7.4.1. Europe: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.3. Subcutaneous Immunoglobulin Market - UK
      • 7.4.3.1. UK: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.4. Subcutaneous Immunoglobulin Market - France
      • 7.4.4.1. France: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.5. Subcutaneous Immunoglobulin Market - Germany
      • 7.4.5.1. Germany: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.6. Subcutaneous Immunoglobulin Market - Italy
      • 7.4.6.1. Italy: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.7. Subcutaneous Immunoglobulin Market - Spain
      • 7.4.7.1. Spain: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.8. Subcutaneous Immunoglobulin Market - Netherlands
      • 7.4.8.1. Netherlands: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.9. Subcutaneous Immunoglobulin Market - Russia
      • 7.4.9.1. Russia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.5. Subcutaneous Immunoglobulin Market - Asia Pacific
    • 7.5.1. Asia Pacific: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.3. Subcutaneous Immunoglobulin Market - China
      • 7.5.3.1. China: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.4. Subcutaneous Immunoglobulin Market - India
      • 7.5.4.1. India: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.5. Subcutaneous Immunoglobulin Market - Malaysia
      • 7.5.5.1. Malaysia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.6. Subcutaneous Immunoglobulin Market - Japan
      • 7.5.6.1. Japan: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.7. Subcutaneous Immunoglobulin Market - Indonesia
      • 7.5.7.1. Indonesia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.8. Subcutaneous Immunoglobulin Market - South Korea
      • 7.5.8.1. South Korea: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.6. Subcutaneous Immunoglobulin Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.3. Subcutaneous Immunoglobulin Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.4. Subcutaneous Immunoglobulin Market - UAE
      • 7.6.4.1. UAE: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.5. Subcutaneous Immunoglobulin Market - Israel
      • 7.6.5.1. Israel: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.6. Subcutaneous Immunoglobulin Market - South Africa
      • 7.6.6.1. South Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.7. Subcutaneous Immunoglobulin Market - Latin America
    • 7.7.1. Latin America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.7.3. Subcutaneous Immunoglobulin Market - Mexico
      • 7.7.3.1. Mexico: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.7.4. Subcutaneous Immunoglobulin Market - Brazil
      • 7.7.4.1. Brazil: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.7.5. Subcutaneous Immunoglobulin Market - Argentina
      • 7.7.5.1. Argentina: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. ADMA Biologics
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bio Product Laboratory
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Biotest AG
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. China Biologic Products Holdings, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. CSL Behring
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6.Emergent BioSolutions
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Grifols
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Hansa Biopharma
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. InVivo Biotech Services
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Kedrion Biopharma
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Kamada Ltd.
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Laboratoire francais du Fractionnement et des Biotechnologies
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Octapharma
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Shenzhen Weiguang Biological Products Co., Ltd.
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Takeda Pharmaceutical Company
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development

List of Tables

  • Table 1 Global Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 2 Global Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Subcutaneous Immunoglobulin Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 5 North America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 6 U.S.: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 7 U.S.: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 8 Canada: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 9 Canada: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 10 Europe: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 11 Europe: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 12 UK: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 13 UK: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 14 France: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 15 France: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Germany: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 17 Germany: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 18 Italy: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 19 Italy: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 20 Spain: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 21 Spain: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 24 Russia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 25 Russia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 28 China: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 29 China: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 30 India: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 31 India: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Japan: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 35 Japan: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 38 South Korea: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 39 South Korea: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 44 UAE: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 45 UAE: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 46 Israel: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 47 Israel: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 48 South Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 49 South Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 50 Latin America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 51 Latin America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Mexico: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 53 Mexico: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 54 Brazil: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 55 Brazil: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 56 Argentina: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 57 Argentina: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Subcutaneous Immunoglobulin Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by End Use
  • Figure 7 Global Subcutaneous Immunoglobulin Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Application
  • Figure 9 Global Subcutaneous Immunoglobulin Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 10 Subcutaneous Immunoglobulin Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Subcutaneous Immunoglobulin Market